Table 3.

HLA/Antigen complexes recognized by TIL infused to R-patients (n = 25)

Patient	HLA-A	HLA-B	HLA-C	HLA/Antigen recognized
Positive TIL populations (n = 13)a
M99	A*2901	B*4001–4403	Cw*0304–1601	A*2901/gp100
				B*4001/gp75
M110	A*0301–1101	B*3501	Cw*0401–0602	B*3501/gp100
M113	A*0201	B*0702–1302	Cw*0602–0702	A*0201/Melan-A
M115	A*0201–2901	B*4901–4402	Cw*0501–0701	B*4901/tyrosinase
M125	A*0201–1101	B*2705–3501	Cw*0702–0401	B*3501/PRAME
M131	A*0201–1101	B*3501	Cw*0602–0202	A*0201/Melan-A
M148	A*0201–1101	B*3501–5101	Cw*0401–1502	A*0201/tyrosinase
				B*3501/tyrosinase
				Cw*0401/tyrosinase
M167	A*2402	B*4001	Cw*0304	A*2402/GAGE
M171	A*0101–0201	B*0801–3501	Cw*0401–0701	A*0201/Melan-A/PRAME/tyr.
				B*3501/Melan-A/tyr./gp100
M199	A*0201–0101	B*0801	Cw*0701–1402	A*0201/Melan-A
				A*0101/gp100
M200	A*0201–0101	B*1801	Cw*0701	A*0201/tyrosinase
M204	A*0201	B*5101–5501	Cw*0303–1502	A*0201/Melan-A/tyrosinase
M212	A*2901–3201	B*0702	Cw*0602–0702	A*2901/MAGE-A3
Negative TIL populations (n = 12)b
M100	A*0201–3201	B*4402	Cw*0401–0501	–
M126	A*0301	B*3501	Cw*0401–0602	–
M132	A*0201–2402	B*4402	Cw*0303–0501	–
M144	A*0101–2401	B*0801–1402	nd	–
M145	A*0201–2901	B*0702–4402	Cw*0102–0501	–
M149	A*0201	B*3508–0702	Cw*0702–0602	–
M153	A*0201–2901	B*0801	Cw*0701–1402	–
M164	A*6802	B*1801–1402	Cw*0501–0802	–
M192	A*0201–2902	B*4501–5101	Cw*0602–1402	–
M193	A*2501–3301	B*1402–1801	Cw*0802–1203	–
M196c	A*0201–1101	B*4403	Cw*1601–0304	–
M209c	A*1101	B*1801–3501	Cw*0403–0501	–

^aThe TIL populations that recognized at least one of the tested antigens in one HLA context

^bNo recognition of any HLA/antigen combination tested

^cMelanoma patients with only one invaded lymph node at treatment